Phase 1/2 study of cetuximab plus capecitabine in elderly patients with kras-wild type mCRC who have no prior chemotherapy

Phase 1/2 study of cetuximab plus capecitabine in elderly patients with kras-wild type mCRC who have no prior chemotherapy - CC with elderly kras-wild type mCRC

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004579

Enrollment

Registered

2011-02-08

Start date

2010-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

unresectable metastatic colorectal cancer

Interventions

capecitabine,cetuximab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Kras wild type over 80 no prior chemotherapy unresectable CRC PS=0,1 keep good orgun function

Exclusion criteria

Exclusion criteria: Surgery or irradiation within 4weeks befor trial entry Uncontrolled comobirity Active infection unable to intake Pulmonary fibrosis, interstital pneumonia with previous medical history

Design outcomes

Primary

Measure	Time frame
Safety/efficacy	—

Secondary

Measure	Time frame
PFS,OS	—

Countries

Japan

Contacts

Public ContactYasutoshi KUBOKI

Cancer institute hospital medical oncology

yasutoshi.kuboki@jfcr.or.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026